Call Us: 888-488-5750

Reimbursement Headwinds and the Rise of Revenue Resilience

Across the healthcare landscape, hospitals, infusion centers, and outpatient facilities are facing mounting financial pressure. In 2025, CMS reimbursement adjustments, biosimilar pricing shifts, and increased payer scrutiny have made maintaining predictable revenue more challenging than ever.

While some organizations tighten budgets or defer expansion plans, others are taking a more strategic approach, turning to Strategic Rebate Management as a lever for financial resilience.

From Recovery to Strategy

Rebate management has evolved far beyond simple recovery. Leading outpatient and infusion providers now view it as a precision tool for stabilizing margins and strengthening long-term financial health.

Unlike short-term fixes, strategic rebate programs identify and recover manufacturer rebates already embedded in Part B drug claims, funds that are earned but often missed due to administrative complexity or lack of visibility.

When one infusion network partnered with VativoRx, only 7% of total claims were rebate-eligible, yet that small, fully compliant subset generated a six-figure impact. This outcome highlights that the real advantage of a modern rebate strategy lies in identifying the right volume and claim types, with compliance and precision built in.

Compliance at the Core

Healthcare executives are rightfully cautious about anything that touches reimbursement. That’s why compliance sits at the heart of VativoRx’s approach to Strategic Rebate Management.

Our system integrates over 100 automated eligibility and compliance checks, including 340B and GPO validation, HITRUST-certified data security, and audit-ready reporting. Every claim submitted meets strict manufacturer and CMS criteria, ensuring full transparency and protecting organizations from clawbacks or audit exposure.

The Financial Case for Resilience

In a reimbursement environment where underpayments and margin compression are the new normal, strategic rebate management offers a sustainable way to strengthen EBITDA and support growth initiatives.

For outpatient and infusion centers, this can translate into:

  • Reliable, compliant revenue flow
  • Greater confidence in financial forecasting
  • Capital to reinvest in patient care or expansion

Strategic rebate management isn’t reactive, it’s a framework for building resilience through precision.

Moving Forward

As healthcare organizations prepare for 2026 and beyond, those who adopt data-driven, compliant rebate programs will be best positioned to weather financial uncertainty and capture every eligible dollar already within their reach.

👉 Learn more about VativoRx’s Strategic Rebate Management solutions and how we help outpatient and infusion facilities achieve sustainable growth. Explore our solutions →


Disclaimer

Informational only; not legal/regulatory advice. Outcomes vary by claim volume & type, program terms, contracts, and law. Past results aren’t guarantees.

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »